Bayer begins phase 3 trial testing aflibercept in infant blindnessBayer has begun a late-stage trial of its blockbuster aflibercept eye drug to prevent blindness in premature infants. Share XBayer begins phase 3 trial testing aflibercept in infant blindnesshttps://pharmaphorum.com/news/bayer-begins-phase-3-trial-testing-aflibercept-in-infant-blindness/
Bayer’s regorafenib kicks off brain cancer platform trialBayer has become the first pharma company to take part in a new platform trial designed to find Share XBayer’s regorafenib kicks off brain cancer platform trialhttps://pharmaphorum.com/news/bayers-regorafenib-kicks-off-brain-cancer-platform-trial/
Japan approves Roche’s tumour agnostic cancer drug RozlytrekJapan has become the first country to approve Roche’s personalised cancer drug Rozlytrek (entrectinib). Roche added entrectinib to Share XJapan approves Roche’s tumour agnostic cancer drug Rozlytrekhttps://pharmaphorum.com/news/japan-approves-roches-tumour-agnostic-cancer-drug-rozlytrek/
Bayer buys into Arvinas protein degrader discovery platformBayer is paying $17.5 million upfront to US biotech Arvinas, tapping into a protein-targeting platform to seek new Share XBayer buys into Arvinas protein degrader discovery platformhttps://pharmaphorum.com/news/bayer-buys-into-arvinas-protein-degrader-discovery-platform/
Bayer’s Aliqopa gets speedy review for marginal zone lymphomaThe FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) Share XBayer’s Aliqopa gets speedy review for marginal zone lymphomahttps://pharmaphorum.com/news/bayers-aliqopa-gets-speedy-review-for-marginal-zone-lymphoma/
Digital therapeutics start-ups need patience as well as patientsAn entirely new category of medicine is emerging, and a new wave of digital therapeutics start-ups is joining Share XDigital therapeutics start-ups need patience as well as patientshttps://pharmaphorum.com/views-analysis-digital/bayer-g4a-digital-therapeutics-startups/
FDA approves Regeneron’s Eylea for diabetic retinopathyRegeneron’s Eylea injection has been approved in the US for diabetic retinopathy, to treat all stages of the Share XFDA approves Regeneron’s Eylea for diabetic retinopathyhttps://pharmaphorum.com/news/fda-approves-regenerons-eylea-for-diabetic-retinopathy/
The sky’s the limit for the right digital health start-upsWhat started out six years ago as a local ‘passion project’ for Bayer to collaborate with Berlin’s digital Share XThe sky’s the limit for the right digital health start-upshttps://pharmaphorum.com/views-analysis-digital/bayer-g4a-digital-health-startups/
Novartis files potential blockbuster eye drug with FDANovartis has filed its ophthalmology drug brolucizumab with the US regulator, a potentially strong competitor in the tough Share XNovartis files potential blockbuster eye drug with FDAhttps://pharmaphorum.com/news/novartis-files-potential-blockbuster-eye-drug/
